Kelli Carr
Nurse Practitioner · Livingston, TNNPI 1245655299
Payments from drug & device makers
Across 152 payments — averaging $16.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- Xeris Pharmaceuticals, Inc.$157
- Lilly USA, LLC$146
- Boehringer Ingelheim$130
- Abbott$93
- Amgen$73
- plus $779 from 24 others
What the payments were for
- Food & beverage$2,569100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 69 | $1,191 |
| Xeris Pharmaceuticals, Inc. | 8 | $157 |
| Lilly USA, LLC | 10 | $146 |
| Boehringer Ingelheim | 9 | $130 |
| Abbott | 5 | $93 |
| Amgen | 5 | $73 |
| Eisai Inc. | 4 | $68 |
| Amarin Pharma, Inc. | 4 | $64 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $53 |
| Vifor Pharma, Inc. | 4 | $49 |
| Exact Sciences | 3 | $49 |
| Cranial Technologies, Inc | 3 | $48 |
| Edwards Lifesciences | 1 | $43 |
| Bayer | 2 | $36 |
| AstraZeneca | 3 | $36 |
| Sanofi Pasteur Inc. | 2 | $33 |
| GSK | 2 | $32 |
| AbbVie | 2 | $32 |
| Johnson & Johnson | 2 | $31 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $26 |
| Biohaven Pharmaceuticals, Inc. | 1 | $26 |
| Corium, LLC | 1 | $22 |
| Kyowa Kirin, Inc. | 1 | $22 |
| SK Life Science, Inc. | 1 | $19 |
| Corcept Therapeutics | 1 | $18 |
| Paratek Pharmaceuticals, Inc. | 1 | $16 |
| Pfizer | 1 | $15 |
| Otsuka America Pharmaceutical, Inc. | 1 | $14 |
| CMP Pharma, Inc. | 1 | $14 |
| Scilex Pharmaceuticals Inc. | 1 | $13 |
How this compares
$2,569 in reported general payments places this provider in the 80th percentile of 2,662 nurse practitioner providers in Tennessee.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 13 | $7,268 |
| Famotidine | 12 | $271 |
| Simvastatin | 12 | $46 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $15 | $7,26813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,662 nurse practitioner providers in Tennessee.
Other nurse practitioner in Livingston
- Amy HatcherMurfreesboro$1.1M
- Karen RodenKnoxville$265K
- Susan UtleyNashville$194K
- Whitney EricksonMemphis$159K
- Erica HembreeKnoxville$125K
- Brooke FaughtNashville$89K
- Lauren WelchNashville$71K
- Cara StoutKingsport$71K
- S Marie HamiltonOoltewah$64K
- Cynthia WilsonChattanooga$62K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.